CBPO - China Biologic Products Holdings, Inc.
94.47 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 95.00 |
| Open | 94.60 |
| Bid | 94.31 x 800 |
| Ask | 94.47 x 800 |
| Day's Range | 93.54 - 95.08 |
| 52 Week Range | 60.08 - 107.44 |
| Volume | 99,536 |
| Avg. Volume | 244,219 |
| Market Cap | 3.681B |
| Beta (3Y Monthly) | 0.93 |
| PE Ratio (TTM) | 26.56 |
| EPS (TTM) | 3.56 |
| Earnings Date | Aug 1, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.14 |
- Markit•7 days ago
See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding CBPO is favorable, with net inflows of $1.23 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Motley Fool•last monthChina Biologic Products Inc (CBPO) Q1 2019 Earnings Call Transcript
CBPO earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates
China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
China Biologic Products: 1Q Earnings Snapshot
The Beijing-based company said it had net income of 94 cents per share. Earnings, adjusted for non-recurring costs, were $1.11 per share. The biopharmaceutical company posted revenue of $129.8 million ...
- PR Newswire•2 months ago
China Biologic Reports Financial Results for the First Quarter of 2019
--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million ; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING , May 10, 2019 /PRNewswire/ ...
- Zacks•2 months ago
Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
China Biologic Products to Report First Quarter 2019 Financial Results
BEIJING , April 30, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Insider Monkey•2 months ago
Is China Biologic Products Inc (CBPO) A Good Stock To Buy According To Hedge Funds?
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Zacks•2 months ago
Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•3 months ago
New Strong Sell Stocks for April 9th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- Zacks•3 months ago
New Strong Sell Stocks for March 22nd
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•3 months ago
New Strong Sell Stocks for March 18th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Motley Fool•4 months agoChina Biologic Products Inc (CBPO) Q4 2018 Earnings Conference Call Transcript
CBPO earnings call for the period ending December 31, 2018.
- PR Newswire•4 months ago
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018
-- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million ; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total Sales ...
- PR Newswire•4 months ago
China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results
BEIJING , Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Insider Monkey•5 months ago
Dalton Investments’ Return, AUM, and Holdings
Exactly 30 years ago, Steve Persky, James Rosenwald, and Gifford Combs joined together to form Dalton Investments, a Santa Monica – based hedge fund. What made these three businessmen join together as a team was a serious investment experience in Asia and a vision of an investment management firm with a main focus on the […]
